Free tool
FAERS Monitor: Evamist
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022014 or its brand name (Evamist, Estradiol). Reports on generic versions are filed under their own applications.
Reports
47,405
Serious
22,633
48% of reports
Hospitalization
7,265
Death reported
909
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,872
- headache2,922
- fatigue2,894
- nausea2,892
- off label use2,418
- pain2,093
- diarrhoea1,961
- dizziness1,736
- breast cancer female1,709
- arthralgia1,646
- pruritus1,568
- rash1,545
- product adhesion issue1,536
- dyspnoea1,535
- insomnia1,360
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 524 |
| 2005 | 571 |
| 2006 | 402 |
| 2007 | 1,461 |
| 2008 | 431 |
| 2009 | 601 |
| 2010 | 972 |
| 2011 | 851 |
| 2012 | 1,160 |
| 2013 | 889 |
| 2014 | 1,117 |
| 2015 | 1,923 |
| 2016 | 2,394 |
| 2017 | 2,181 |
| 2018 | 2,581 |
| 2019 | 2,912 |
| 2020 | 2,914 |
| 2021 | 2,861 |
| 2022 | 3,093 |
| 2023 | 3,561 |
| 2024 | 3,713 |
| 2025 | 5,259 |
| 2026 | 5,033 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,006,754 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 1,709 | 30.3 | 28.8 | 45,287 |
| product adhesion issueSignal | 1,536 | 19.9 | 18.9 | 26,392 |
| insomniaSignal | 1,360 | 2.3 | 2.2 | 975 |
| headacheSignal | 2,922 | 2.1 | 2.0 | 1,663 |
| pruritus | 1,568 | 1.8 | 1.7 | 580 |
| arthralgia | 1,646 | 1.8 | 1.7 | 548 |
| fatigue | 2,894 | 1.7 | 1.6 | 769 |
| nausea | 2,892 | 1.6 | 1.6 | 716 |
| rash | 1,545 | 1.6 | 1.5 | 329 |
| dizziness | 1,736 | 1.5 | 1.5 | 341 |
| pain | 2,093 | 1.5 | 1.5 | 374 |
| diarrhoea | 1,961 | 1.3 | 1.3 | 182 |
| drug ineffective | 3,872 | 1.3 | 1.3 | 292 |
| off label use | 2,418 | 1.2 | 1.2 | 104 |
| dyspnoea | 1,535 | 1.2 | 1.1 | 54 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.